Reply letter to the commentary on "Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study"
Int J Surg. 2024 Dec 20.
doi: 10.1097/JS9.0000000000002162.
Online ahead of print.
1 Toxicology Research Center, Shandong Academy of Occupational Health and Occupational Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
2 Breast Disease Department, Weifang People's Hospital, The First Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, China.